ConductScience.org, home

Comparison · NCT02265796-deaths

Ranolazine vs Sugar Pill: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ranolazine vs Sugar Pill: deaths from any cause. Trial comparisons, record NCT02265796-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02265796-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.040.00710.195wilson
Risk in group 200.00000000000000001390.133wilson
Risk difference, group 1 minus group 20.04-0.09720.195newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Ranolazine than on Sugar Pill25from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ranolazine
Ranolazine 500 mg tablets~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks~Ranolazine: Ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks
125EG000
Group 2Sugar Pill
Sugar pill that looks like the drug ranolazine 500mg tablet~1. 500mg tablet two times per day for 7 days then,~2. 500mg tablet (1000mg) two times per day for 15 weeks~Sugar pill: 1. 500mg tablet two times per day for 7 days then, 2. 500mg tablet (1000mg) two times per day for 15 weeks
025EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Baseline to 16 weeks

Source ClinicalTrials.gov

Trial

Title
Ranolazine Among Unrevascularized Chronic Stable Angina Patients
NCT number
NCT02265796
Phases
PHASE2
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Lead sponsor
North Florida Foundation for Research and Education
Results first posted
2017-12-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02265796-deaths